Validation of the MSKCC score model in advanced renal cell carcinoma patients treated with VEGF-targeted agents in China
10.3760/cma.j.issn.1000-6702.2013.02.018
- VernacularTitle:MSKCC生存危险度分组在中国肾癌靶向治疗人群中的验证
- Author:
Yaping HONG
;
Yao ZHU
;
Xudong YAO
;
Shilin ZHANG
;
Bo DAI
;
Hailiang ZHANG
;
Yijun SHEN
;
Yiping ZHU
;
Chunguang MA
;
Wenjun XIAO
;
Xiaojian QIN
;
Guowen LIN
;
Dingwei YE
- Publication Type:Journal Article
- Keywords:
Carcinoma,renal cell;
Molecular targeted therapy;
Prognosis;
Memorial Sloan-Kettering Cancer Center risk groups
- From:
Chinese Journal of Urology
2013;(2):143-146
- CountryChina
- Language:Chinese
-
Abstract:
Objective To validate the Memorial Sloan-Kettering Cancer Center(MSKCC)score model and evaluate the clinical efficacy of vascular endothelial growth factor(VEGF)-targeted agents in the treatment of advanced renal cell carcinoma(RCC)in China.Methods Three hundred and forty-five patients with advanced RCC and average age of 57(17-90)years were treated with VEGF-targeted agents.There were 306 cases of clear cell RCC,20 cases of papillary RCC,4 cases of chromophobe RCC,5 cases of renal collecting duct carcinoma,3 cases of medullary carcinoma and 7 cases of unclassified RCC.The main metastatic lesions were located at lung,bone and lymph nodes.Of them,205 cases were given the treatment of sorafenib 400 mg bid without off treatment,while 140 cases received sunitinib treatment in repeated six week cycles consisting of four weeks of sunitinib 50 mg daily followed by two weeks off treatment.Overall survival(OS)was estimated by the Kaplan-Meier method.Log-rank test and Harrell concordance index analysis were used to validate the MSKCC score model.Results The median follow-up period were 23(1-68)months in the whole group.The OS was 33 months,and survival rates at 1,2,3 year were 77.6％,59.3％,46.6％,respectively.According to the MSKCC score model,the patients were segregated into three risk categories: the favorable-risk group(no prognostic factors;n =169;49.0％),in which median OS(mOS)was 46 months and 2 year OS was 75.8％;the imtermediate-risk group(one or two prognostic factors;n =150;43.5％),in which mOS was 24 months and 2 year OS was 47.7％;and the poorrisk group(three to five prognostic factors;n =26;7.5％),in which mOS was 8 months and 2 year OS was 10.1％(log-rank P ＜ 0.01).The concordance index was 0.687.Conclusions VEGF-targeted agents are effective in Chinese advanced RCC patients.The MSKCC score model can be incorporated into judging individualizing tumor prognosis and communicating about the treatment options with patients who are using VEGF-targeted agents.
